Postulated MRD eradication strategies include CD19‐targeted immune effector engaging therapies as have been successfully purposed in B‐cell acute lymphoblastic leukaemia [31]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.